Lv31
260 积分 2025-12-31 加入
Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy
3天前
已完结
Long-term outcomes of IgA nephropathy in China
3天前
已完结
Global, regional, and national sepsis incidence and mortality, 1990–2021: a systematic analysis
3天前
已完结
11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes—2022
3天前
已关闭
Pharmacokinetics, pharmacodynamics and safety profile of the dual orexin receptor antagonist vornorexant/TS‐142 in healthy Japanese participants following single/multiple dosing: Randomized, double‐blind, placebo‐controlled phase‐1 studies
10天前
已完结
Highly variable aggregation and glycosylation profiles and their roles in immunogenicity to protein-based therapeutics
13天前
已完结
Yangxinshi tablet protects against myocardial injury and increases skeletal muscle exercise capacity by regulating mitochondrial bioenergetics
20天前
已完结
Luvometinib: First Approval
23天前
已完结
Marked Improvement in Soft Tissue and CNS Manifestations of Adult Langerhans Cell Histiocytosis on Targeted MEK Inhibitor Therapy
23天前
已完结
皖公网安备34019202002308
